Evidence map›Paper›PMID 40257628›Full record

ReviewPituitary2025

Epigenetic implications in the pathogenesis of corticotroph tumors.

Ticiana Paes, Leo J Hofland, Anand M Iyer, Richard A Feelders

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ticiana PaesDepartment of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Rotterdam, GD 3015, The Netherlands.
Leo J HoflandDepartment of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Rotterdam, GD 3015, The Netherlands.
Anand M IyerDepartment of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Rotterdam, GD 3015, The Netherlands.
Richard A FeeldersDepartment of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Rotterdam, GD 3015, The Netherlands. r.feelders@erasmusmc.nl.ORCID https://orcid.org/0000-0003-2319-391X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-mutational epigenetic reprogramming is considered an important enabling characteristic of neoplasia. Corticotroph tumors and other subtypes of pituitary tumors are characterized by distinct epigenetic profiles. The DNA methylation profile is consistent with disease-specific gene expression, which highlights the importance of epigenetic changes in tumor formation and progression. Elucidating the epigenetic changes underlying tumorigenesis plays an important role in understanding the molecular pathogenesis of corticotroph tumors and may ultimately contribute to improving tumor-specific treatment. Here, we provide an overview of the epigenetic landscape of corticotroph tumors. We also review the role of epigenetics in silencing the expression of tumor suppressor genes and promoting oncogenes expression, which could potentially be involved in the pathogenesis of corticotroph tumors. We briefly discuss microRNAs and epigenetic aspects of POMC regulation. Lastly, since the epigenetic changes are reversible, we discuss drugs that target epigenetic modifiers that could potentially be used in the arsenal of Cushing's disease treatment modalities.

Indexed as

Epigenesis, GeneticPituitary NeoplasmsAnimalsDNA MethylationGene Expression Regulation, NeoplasticHumansMicroRNAsMicroRNAsCorticotroph tumorsCushing diseaseDNA methylationEpigenetic

Identifiers

PMID40257628
PMCPMC12011945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.